Covid-19 roundup: Vaxart dos­es first pa­tient in new clin­i­cal vac­cine study; NI­AID launch­es study to find po­ten­tial ther­a­pies in re­pur­posed drugs

Cal­i­for­nia-based Vaxart has dosed the first pa­tient in a Phase I study of its Covid-19 can­di­date.

The oral can­di­date, VXA-CoV2-1, will be test­ed in up to 48 vol­un­teers ages 18 to 54 years old. The biotech ex­pects to com­plete en­roll­ment by ear­ly No­vem­ber, and re­ceive the first clin­i­cal da­ta in the next few weeks. The vac­cine could be a one- or two-dose can­di­date, de­pend­ing on the out­come of the study.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER